Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
NIO752B12201
Phase 1 other active
Quick answer
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants for Alzheimer’s Disease is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Alzheimer’s Disease
- Phase
- Phase 1
- Modality
- other
- Status
- active